<DOC>
	<DOCNO>NCT01441440</DOCNO>
	<brief_summary>This phase 3 , multi-center , randomize , double-blind , placebo-controlled , parallel group study evaluate efficacy safety venlafaxine ER 75 mg/day ( fix dose ) venlafaxine ER 75 mg/day 225 mg/day ( flexible dose ) , compare placebo . This study consist 2 week screen phase , 8 week treatment phase 2 week taper phase . The follow-up visit evaluate 2 week last study medication dosing .</brief_summary>
	<brief_title>Venlafaxine ER Phase 3 Study Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Outpatient status . A primary diagnosis MDD base criterion Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSM IVTR ) , single recurrent episode , without psychotic feature . Depressive symptoms least 90 day single episode least 28 day recurrent episode screen visit . A MADRS total score ≥26 screen baseline visit . And change MADRS total score baseline 25 % screen visit . A QIDS16JSR score ≥16 screen baseline visit . A score ≥4 Clinical Global Impressions ScaleSeverity ( CGIS ) screen baseline visit . Subjects concurrently Axis II personality disorder mental retardation accord DSMIV diagnostic criterion . Subjects meet DSMIV criterion current past history Schizophrenia , Paranoid Disorders , Psychotic Disorders . Subjects meet DSMIV criterion current past history Dementia . Subjects meet DSMIV criterion current past history bipolar disorder , Posttraumatic Stress Disorder ( PTSD ) Obsessive Compulsive Disorder ( OCD ) . Subjects meet DSMIV criterion current ( within 12 month screen visit ) generalize anxiety disorder , panic disorder , social anxiety disorder consider investigator primary ( cause high degree distress impairment MDD ) . Subjects first degree relative bipolar disorder . Subjects actively suicidal . History nonresponsive 2 antidepressant treatment ( least 6week usage ) past current episode . History Electroconvulsive therapy ( ECT ) time past . History chronic treatment benzodiazepine longer 6 month screen visit ( Excluding subject take PRN benzodiazepine use , &lt; 3 times/week ) . Any unstable hepatic , renal , pulmonary , cardiovascular ( include uncontrolled hypertension ) , ophthalmologic , neurologic , medical condition investigator 's judgment , substantially increase risk associate subject 's participation completion , study . Known presence raise intraocular pressure history presence narrow angle glaucoma . Myocardial infarction within 180 day screen visit . Clinically important abnormality , determine investigator , screen physical examination , electrocardiogram ( ECG ) laboratory test . Use prohibit treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>venlafaxine ER</keyword>
	<keyword>Major depressive disorder</keyword>
	<keyword>Japan</keyword>
	<keyword>placebo-controlled</keyword>
</DOC>